<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01359982</url>
  </required_header>
  <id_info>
    <org_study_id>RRx001-11-01</org_study_id>
    <nct_id>NCT01359982</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects</brief_title>
  <acronym>DINAMIC</acronym>
  <official_title>A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of RRx-001 in Subjects With Advanced Solid Tumors or Lymphomas For Which There Are No Currently Accepted Curative Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EpicentRx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EpicentRx, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and pharmacokinetic profile of RRx-001&#xD;
      for injection in subjects with advanced solid tumors or lymphomas for which there are no&#xD;
      currently accepted curative therapies. This study will also conduct an exploratory evaluation&#xD;
      of objective tumor response using CT or MRI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The DINAMIC (DINitroazetidines As Medications In Cancer) trial represents a provascular&#xD;
      approach to temporarily change tumor blood flow and oxygenation. Blood supply to most tumors&#xD;
      is poor, causing parts of tumors to have a low oxygen content which promotes aggressiveness&#xD;
      and metastasis. The DINAMIC trial uses specific imaging techniques (including ultrasound),&#xD;
      biopsy, and breath analysis to provide an early assessment of therapeutic activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number, frequency and type of adverse events</measure>
    <time_frame>92 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Malignant Solid Tumor</condition>
  <condition>Lymphomas</condition>
  <arm_group>
    <arm_group_label>RRx-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RRx-001</intervention_name>
    <description>Dose level 1 (10 mg/m2)</description>
    <arm_group_label>RRx-001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RRx-001</intervention_name>
    <description>Dose Level 2 (16.7 mg/m2)</description>
    <arm_group_label>RRx-001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RRx-001</intervention_name>
    <description>Dose Level 3 (24.6 mg/m2)</description>
    <arm_group_label>RRx-001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RRx-001</intervention_name>
    <description>Dose Level 4 (33 mg/m2)</description>
    <arm_group_label>RRx-001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RRx-001</intervention_name>
    <description>Dose Level 5 (55.0 mg/m2)</description>
    <arm_group_label>RRx-001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RRx-001</intervention_name>
    <description>Dose Level 6 (83 mg/m2)</description>
    <arm_group_label>RRx-001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is male or female, aged at least 18 years.&#xD;
&#xD;
          -  Subject has a histologically or cytologically confirmed diagnosis of an advanced,&#xD;
             malignant, incurable solid tumor(s) or lymphoma that is metastatic and/or unresectable&#xD;
             and/or for which standard curative measures either are not applicable, or do not&#xD;
             exist, or are no longer effective. Subjects with curative treatment options are not&#xD;
             eligible for the protocol.&#xD;
&#xD;
          -  Subject is not receiving any active treatment for his/her malignancy (except for&#xD;
             prostate cancer subjects receiving luteinizing hormone-releasing hormone (LHRH)&#xD;
             agonists and antiandrogens such as: Flutamide, Dutasteride, and Finasteride).&#xD;
&#xD;
          -  Subject's Eastern Cooperative Group (ECOG) performance status is 0, 1 or 2 at&#xD;
             Screening.&#xD;
&#xD;
          -  Subject has acceptable liver function at Screening&#xD;
&#xD;
          -  Subject has a normal serum creatinine.&#xD;
&#xD;
          -  Subject has acceptable hematologic status at Screening&#xD;
&#xD;
          -  Female subjects of childbearing potential (i.e., women who have not been surgically&#xD;
             sterilized or have not been post-menopausal for at least one year), and male subjects&#xD;
             with partners of childbearing potential, must agree to use medically acceptable&#xD;
             methods of contraception beginning on Study Day 1 and continuing until at least four&#xD;
             weeks after administration of the subject's final dose of RRx-001.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Impaired cardiac function that in the opinion of the Investigator could interfere with&#xD;
             the conduct of the study or could put the subject at unacceptable risk.&#xD;
&#xD;
          -  Right-to-left, bidirectional, or transient right-to-left cardiac shunts.&#xD;
&#xD;
          -  Subjects with a history of acute cerebral infarction or transient ischemic attack&#xD;
             within 90 days prior to Study Day 1.&#xD;
&#xD;
          -  Acute myocardial infarction or acute coronary syndromes less than one year prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Serious ventricular arrythmias or high risk for arrhythmias due to prolongation of the&#xD;
             QT interval.&#xD;
&#xD;
          -  Subjects who experienced a major surgery, radiotherapy, or immunotherapy within the&#xD;
             last 21 days prior to Study Day 1 (limited palliative radiation is allowed within 14&#xD;
             days prior to Study Day 1).&#xD;
&#xD;
          -  Chemotherapy regimens with delayed toxicity within the 28 days prior to Study Day 1&#xD;
             (except for nitrosourea or mitomycin C treatments within 42 days prior to Study Day&#xD;
             1).&#xD;
&#xD;
          -  Chemotherapy regimens given continuously or on a weekly basis that Investigator&#xD;
             believes to have a limited potential for delayed toxicity within 14 days prior to&#xD;
             Study Day 1.&#xD;
&#xD;
          -  Use of an investigational anti-cancer drug within 42 days prior to Study Day 1.&#xD;
&#xD;
          -  Subject has symptomatic and/or untreated central nervous system metastases and/or&#xD;
             intracranial hypertension.&#xD;
&#xD;
          -  Subject has a known history of an active and/or an uncontrolled infection with&#xD;
             hepatitis A or hepatitis B.&#xD;
&#xD;
          -  Subject with a known history of a positive HIV status.&#xD;
&#xD;
          -  Subjects with pulmonary edema.&#xD;
&#xD;
          -  Subjects with respiratory failure&#xD;
&#xD;
          -  Subjects with severe emphysema, pulmonary emboli, pulmonary fibrosis or other&#xD;
             conditions that cause pulmonary hypertension due to compromised pulmonary arterial&#xD;
             vasculature.&#xD;
&#xD;
          -  Subjects with Raynaud's syndrome.&#xD;
&#xD;
          -  Subjects with a serious co-morbid medical condition.&#xD;
&#xD;
          -  If female, subject is pregnant and/or breastfeeding.&#xD;
&#xD;
          -  Any subject with congenital or acquired methemoglobinemia.&#xD;
&#xD;
          -  Any subject with a history of inherited anemia or hemoglobinopathy including but not&#xD;
             limited to hereditary spherocytosis, hereditary elliptocytosis, hereditary&#xD;
             ovalocytosis,&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Infante, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SCRI Development Innovations, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tony Reid, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moores University of California San Diego Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>May 23, 2011</study_first_submitted>
  <study_first_submitted_qc>May 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2011</study_first_posted>
  <last_update_submitted>May 19, 2015</last_update_submitted>
  <last_update_submitted_qc>May 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumors</keyword>
  <keyword>Lymphomas</keyword>
  <keyword>Safety</keyword>
  <keyword>Blood flow</keyword>
  <keyword>Nitric oxide</keyword>
  <keyword>Cancer</keyword>
  <keyword>Dynamic contrast enhanced MRI (DCE-MRI)</keyword>
  <keyword>Contrast Enhanced Ultrasound (CEUS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

